

Accepted as an oral presentation at the World Congress on Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases (WCO-IOF-ESCEO) 2020, August 20–22, 2020

The Novel, Intra-articular CLK/DYRK1A Inhibitor Lorecivivint (SM04690), a Wnt Pathway Modulator, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial

Jeyanesh Tambiah, MD, Sarah Kennedy, PhD, Christopher J. Swearingen, PhD, Yusuf Yazici, MD

Samumed, LLC, San Diego, CA

Background: Lorecivivint (LOR; SM04690) is a small-molecule, intra-articular (IA) CLK/DYRK1A inhibitor that modulates the Wnt pathway and has demonstrated beneficial effects on patient-reported outcomes (PROs) compared with placebo (PBO) in two Phase 2 knee osteoarthritis (OA) trials. Representing PROs as discrete threshold responses instead of as changes in mean point estimates may more meaningfully evaluate clinical benefits experienced by trial subjects. This post hoc analysis was conducted to measure the proportion of LOR-treated subjects in a 24-week Phase 2b trial who achieved 30%, 50%, or 70% threshold responses over baseline in Pain Numeric Rating Scale (NRS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) subscores, and Patient Global Assessment (PtGA). Results from the Phase 3-selected dose of 0.07 mg LOR are presented here.

Methods: Subjects had ACR-defined knee OA, Kellgren-Lawrence grades 2–3, and Pain NRS scores ≥ 4 and ≤ 8 in the target knee and < 4 in the contralateral knee. A single 2 mL IA injection of 0.03 mg, 0.07 mg, 0.15 mg, or 0.23 mg LOR or vehicle PBO was given in the target knee at baseline. The proportion of subjects meeting 30%, 50%, or 70% threshold responses over baseline in the weekly average of daily Pain NRS [0–10], WOMAC Pain [0–100], WOMAC Function [0–100], and PtGA [0–100] at Week 12 was determined. The odds ratios (OR [95%CI]) of achieving each threshold response level were calculated.


Results: 635 subjects (91.4%) completed the trial. Treatment with 0.07 mg LOR versus PBO at Week 12 led to

1. Significantly ($P < 0.05$) increased odds of achieving a 30% threshold response in Pain NRS (OR 2.47 [1.45, 4.19]) and WOMAC Function (OR 1.86 [1.10, 3.12])
2. Significantly increased odds of achieving a 50% threshold response in WOMAC Pain (OR 1.79 [1.06, 3.03]) and PtGA (OR 2.28 [1.25, 4.16])
3. Numerically, but not significantly, more subjects achieving a 70% threshold response in all PROs

Improvements were maintained through Week 24.

Conclusion: LOR, in development as a potential disease-modifying knee OA drug, demonstrated significantly higher odds ratios of achieving and maintaining clinically relevant improvements in PROs compared with placebo from Week 12 through Week 24. Phase 3 trials are ongoing.

Figure: Responder outcomes from a Phase 2b trial of LOR: Pain NRS, WOMAC Pain, WOMAC Function, and Patient Global Assessment at Week 12.



Logistic regression of LOR versus placebo using the Full Analysis Set (FAS, all dosed subjects) and non-responder imputation. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$